AEYE Health, a leading company for AI retinal imaging and diagnostics, has received FDA clearance for the first fully autonomous AI that diagnoses referable diabetic retinopathy. The breakthrough technology uses retinal images obtained by a handheld camera to screen for the leading cause of blindness in the working-age population. The combination of a fully autonomous AI with a portable handheld device allows for an affordable screening solution that can be used anywhere, making it particularly suitable for point-of-care screening. With over 99% of images being usable and the option for patients to be screened at home, AEYE Health's innovation could prevent blindness in millions of people.